Loading…
Loading…
EQUITY / NASDAQ · XNCM
Niki BioSolutions Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →01/01/2025 – 12/31/2025 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗4.6 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 4.6 USD · Volume 13,251
21 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
3 available financial reports
Research reports →SEC FINANCIAL REPORTS
01/01/2025 – 12/31/2025 · Units
| Metric | 2025 / Year end | 2024 / Year end | Change |
|---|---|---|---|
| Net income | -1,363,270 USD | -4,267,806 USD | — |
| Operating cash flow | -1,836,546 USD | -1,189,734 USD | — |
| Cash and cash equivalents | 3,452,891 USD | 874,238 USD | +294.96% |
| Total liabilities | 4,899,823 USD | 4,353,162 USD | +12.56% |
| Total equity | 23,115,160 USD | 21,134,514 USD | +9.37% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2024 / Year end01/01/2024 – 12/31/2024ConsolidatedUnits · USD | 2023 / Year end01/01/2023 – 12/31/2023ConsolidatedUnits · USD |
|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 3,452,891 USD | 874,238 USD | — |
| Financing cash flowCash flow statement | 4,415,199 USD | — | 4,092,068 USD |
| Net incomeIncome statement | -1,363,270 USD | -4,267,806 USD | -2,824,647 USD |
| Operating cash flowCash flow statement | -1,836,546 USD | -1,189,734 USD | -7,724,364 USD |
| Total assetsBalance sheet | 18,691,370 USD | 16,130,223 USD | — |
| Total equityBalance sheet | 23,115,160 USD | 21,134,514 USD | 15,383,353 USD |
| Total liabilitiesBalance sheet | 4,899,823 USD | 4,353,162 USD | — |
| Investing cash flowCash flow statement | — | 58,621 USD | 624,767 USD |
| Capital expendituresCash flow statement | — | — | 3,015 USD |
| RevenueIncome statement | — | — | 431,378 USD |
| Report source | Open report ↗ Published: 03/27/2026 | Open report ↗ Published: 03/27/2026 | Open report ↗ Published: 03/27/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.